Abstract
Thrombosis is a frequent complication of polycythemia vera and essential thrombocythemia, but its incidence and predisposing factors in idiopathic myelofibrosis (IM) are unknown. In 18 (11.6%) of 155 patients diagnosed with IM in a single institution, 31 thrombotic events (19 arterial, 12 venous) were registered after a mean follow-up of 4.2 (s.d.: 4.5) years. In six patients, the thrombosis was simultaneous to or appeared a few months before IM diagnosis and 14 had one or more thrombotic episodes. When compared with the general population, a significant increase was observed in the incidence of venous thrombosis (odds ratio 17.5, 95% confidence interval: 10.3–31.4). At multivariate analysis, the initial variables associated with an increased risk of thrombosis were thrombocytosis (platelets >450 × 109/l, P=0.001), presence of one cardiovascular risk factor (arterial hypertension, smoking, hypercholesterolemia, or diabetes, P=0.003), cellular phase of myelofibrosis (P=0.005), and Hb >11 g/dl (P=0.02). Considering post-diagnosis events, the 5-year thrombosis-free survival probability was 90.4% in the series, 80.6% for patients with platelets >450 × 109/l, 82.6% for patients with one cardiovascular risk factor, and 85.1% for those in cellular phase. These results indicate an increased thrombotic risk for IM patients with hyperproliferative features and/or coexistent cardiovascular risk factors.
Similar content being viewed by others
References
Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med 1995; 123: 656–664.
Landolfi R, Marchioli R, Kutti J, Gisslinger H, Patrono C, Barbui T . Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 35: 114–124.
Cortelazzo F, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F et al. Hydroxyurea for patients with essential thrombocythemia and high risk of thrombosis. New Engl J Med 1995; 332: 1132–1136.
Besses C, Cervantes F, Pereira A, Florensa L, Solé F, Hernández-Boluda JC et al. Major vascular complications in essential thrombocythaemia: a study of the predictive factors in a series of 148 patients. Leukemia 1999; 13: 150–154.
Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005; 353: 33–45.
Brodmann S, Passweg JR, Gratwohl A, Tichelli A, Skoda RC . Myeloproliferative disorders: complications, survival and causes of death. Ann Hematol 2000; 79: 312–318.
Ganti AK, Potti A, Koka VK, Pervez H, Mehdi SA . Myeloproliferative syndromes and the associated risk of coronary artery disease. Thrombos Res 2003; 110: 83–86.
Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN . Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 2000; 95: 2226–2233.
Akpek G, McAneny D, Weintraub L . Risks and benefits of splenectomy in myelofibrosis with myeloid metaplasia: a retrospective analysis of 26 cases. J Surg Oncol 2001; 77: 42–48.
Loring LA, Panicek DM, Karpeh MS . Portal system thrombosis after splenectomy for neoplasm or chronic hematologic disorder: is routine surveillance imaging necessary? J Comput Assist Tomogr 1998; 22: 856–860.
Fujita F, Lyass S, Otsuka K, Giordano L, Rosenbaum DL, Khalili TM et al. Portal vein thrombosis following splenectomy: identification of risk factors. Am Surg 2003; 69: 951–956.
Najean Y, Dresch C, Rain JD . The very long-term course of polycythemia: a complement to the previously published data of the Polycythemia Vera Study Group. Br J Haematol 1994; 86: 233–235.
Cervantes F, Alvarez-Larrán A, Talarn C, Gómez M, Montserrat E . Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol 2002; 118: 786–790.
Thiele J, Kvasnicka HM, Boeltken B, Zankovich R, Diehl V, Fischer R . Initial (prefibrotic) stages of idiopathic (primary) myelofibrosis (IMF) – a clinicopathological study. Leukemia 1999; 13: 1741–1748.
Barosi G, Ambrosetti A, Finelli G, Grossi A, Leoni P, Liberato NL et al. The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. Br J Haematol 1999; 104: 730–737.
Lennert K, Naghai K, Schwarze EW . Patho-anatomical features of the bone marrow. Clin Haematol 1975; 43: 331–351.
Fowkes FGR, Housley E, Cawood EHH, Macintyre CCA, Ruckley CV, Prescott RJ . Edinburgh artery study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991; 20: 384–392.
Stewart JA, Dundas R, Howard RS, Rudd AG, Wolfe CDA . Ethnic differences in incidence of stroke: prospective study with stroke register. Br Med J 1999; 318: 967–971.
Heit JA, Silverstein MD, Mohr DN, Petterson TM, Lohse CM, ÓFallon M et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001; 86: 452–463.
Lampe FC, Morris RW, Walker M, Shaper GA, Whincup PH . Trends in rates of different forms of diagnosed coronary heart disease, 1978 to 2000: prospective, population based study of British men. Br Med J 2005; 330: 1046–1049.
Cervantes F, Pereira A, Esteve J, Rafel M, Cobo F, Rozman C et al. Identification of ‘short-lived’ and ‘long-lived’ patients at presentation of idiopathic myelofibrosis. Br J Haematol 1997; 97: 635–640.
Falanga A, Marchetti M, Evangelista V, Manorini S, Oldani M, Giovanelli S et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000; 96: 4261–4266.
Alvarez-Larrán A, García-Pagan JC, Abraldes JG, Arellano E, Reverter JC, Bosch J et al. Increased CD11b neutrophil expression in Budd–Chiari syndrome or portal vein thrombosis secondary to polycythaemia vera. Br J Haematol 2004; 124: 329–335.
Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061.
Kralowics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779–1790.
James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 2005; 434: 1144–1148.
Levine RL, Wadleigh M, Cools J, Eber BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387–397.
Acknowledgements
We are indebted to Dr Juan G Abraldes and Dr Joan-Carles Reverter for their help in the statistical analysis.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cervantes, F., Alvarez-Larrán, A., Arellano-Rodrigo, E. et al. Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution. Leukemia 20, 55–60 (2006). https://doi.org/10.1038/sj.leu.2404048
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404048
- Springer Nature Limited
Keywords
This article is cited by
-
Higher serum uric acid is associated with higher risks of thrombosis and death in patients with primary myelofibrosis
Wiener klinische Wochenschrift (2022)
-
Thrombocytosis and Thrombosis: Is There Really a Correlation?
Current Hematologic Malignancy Reports (2020)
-
A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms
BMC Cancer (2019)
-
CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms
Scientific Reports (2019)
-
High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation
Annals of Hematology (2019)